Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU loses no time in appointing new Commission:

This article was originally published in Clinica

Executive Summary

Following the withdrawal at the end of October by the incoming president of the European Commission, Jose Manuel Dur-o Barroso, of his proposed team of new commissioners, just days before they were due to take up office, a new team has now been accepted. The Council of the European Union adopted a decision on November 19 appointing the president and members of the Commission. The decision will take effect on November 22 and the team will be in office until October 31, 2009. Following the upheaval, there are two new faces in the team - Franco Frattini of Italy (justice, freedom and security) and Andris Piebalgs of Latvia (energy). One Commissioner, Lazlo Kovacs of Hungary, has a new portfolio (taxation and the customs union). The team was approved by the European Parliament on November 18. There are no alterations to the key people for the medical devices and diagnostics industries: Gunter Verheugen remains and enterprise and industry commissioner and Markos Kyprianou as health and consumer protection commissioner.

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT060273

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel